
AMEXHealthcareDrug Manufacturers - Specialty & Generic
最新数据
US$0.8705
−US$0.0895 · -9.32%
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
前收盘价
US$0.8705
−US$0.0895 · -9.32%
盘中时间采用ET。市场数据可能有所延迟。
China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
日内区间
当前US$0.8705
52周区间
当前US$0.8705
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 414.43万 USD | 452.89万 USD | 701.13万 USD | 810.41万 USD | 964.19万 USD |
| 销货成本 | 427.62万 USD | 651.46万 USD | 729.24万 USD | 859.8万 USD | 929.27万 USD |
| 毛利 | −13.2万 USD | −198.56万 USD | −28.11万 USD | −49.39万 USD | 34.93万 USD |
| 研究与开发 | 28.09万 USD | 28.39万 USD | 24.01万 USD | 18.59万 USD | 31.9万 USD |
| 销售、一般及管理费用 | 282.72万 USD | 231.36万 USD | 224.64万 USD | 296.31万 USD | 314.6万 USD |
| 营业费用 | 295.66万 USD | 260.32万 USD | 247.07万 USD | 305.51万 USD | 320.98万 USD |
| 利息收入 | 2003 USD | 6641 USD | 6602 USD | 1.08万 USD | 3035 USD |
| 利息支出 | 10.2万 USD | 15.41万 USD | 33.36万 USD | 43.46万 USD | 54.2万 USD |
| 折旧和摊销 | 157.92万 USD | 261.81万 USD | 275.37万 USD | 270.05万 USD | 308.78万 USD |
| 营业利润 | −308.85万 USD | −458.89万 USD | −275.18万 USD | −354.9万 USD | −286.05万 USD |
| 净利润 | −318.76万 USD | −473.64万 USD | −307.88万 USD | −397.28万 USD | −339.95万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2025年4月15日 | 1:10 | — | — |
股票拆分 | 2024年3月6日 | 1:5 | — | — |
股票拆分 | 2023年3月6日 | 1:10 | — | — |
股票拆分 | 2003年8月15日 | 250:5,451 | — | — |
已生效 2025年4月15日
1:10
已生效 2024年3月6日
1:5
已生效 2023年3月6日
1:10
已生效 2003年8月15日
250:5,451
AI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。